



Joy brings us together



21th Series of Unsecured Corporate Bond (Social Bonds) funding allocation and impact reporting (as of December 2025)

Amount raised	Unallocated amount
20.0 billion yen	0 billion yen (fully allocated)

21th Series of Unsecured Corporate Bond (Social Bonds) funding allocation and impact reporting (as of December 2025)

Project Name:	Capital investment, operation, and procurement of raw materials contributing to the production of raw material powder of Lc-PLASMA, and the research and development of Lc-PLASMA
Project Summary:	Lc-PLASMA is a lactic acid bacteria that supports the maintenance of immunity in healthy people. It has been reported in research papers that it is the first in the world(Note 1) to work on pDC (plasmacytoid dendritic cells), a leader of the immune system. Kirin Holdings, KOIWA DAIRY PRODUCTS CO., LTD., and KYOWA HAKKO BIO CO., LTD. have jointly conducted research on this product, and with the cooperation of universities and research institutions in Japan and overseas, 33 papers have been published and numerous presentations made at academic conferences. In May 2023, Kirin received the Imperial Invention Award at the 2023 National Commendation for Invention sponsored by the Japan Institute of Invention and Innovation. This award was given in recognition of the invention and efforts related to the discovery and commercialization of LC-PLASMA. It was the first time that this award was given for a health food substance and the first time in 59 years that a food company received it. Receipt of the prestigious awards has led to further enhancement of the reputation of Lc-PLASMA as a reliable substance. To meet the increasing demand for Lc-PLASMA, the production facilities of the "iMUSE Health Science Factory" (located in Sayama City, Saitama Prefecture), which manufactures raw materials of Lc-PLASMA, have been expanded and completed at 2022. With this expansion, the annual production capacity of bacterial bodies has doubled compared to before. Going forward, Kirin Group will continue to develop products using " Lc-PLASMA," which originated from over 35 years of research, across the group, supporting the health of each individual while promoting "immune care," and aiming to create a society where people can live brightly and healthily. (Note 1) Lc-PLASMA was the first lactic acid bacteria reported to work on pDC in humans (based on information published in PubMed and the homepage of the Central Medical Journal).



Amount Allocated (Cumulative): 8.7 billion yen (96.3% Refinanced)

Impact reporting

Categories	Projects	Output	Outcome	FY 2025 commitment result
Businesses that contribute to the achievement of a society of health and longevity, through the maintenance of immune function	Capital investment,operation, and procurement of raw materials contributing to the production of raw material powder of LcPLASMA, and the research and development of Lc-PLASMA	☐ Increase in Lc-PLASMA manufacturing capacity ☐ Number of published papers ☐ Number of conference presentations ☐ Partnerships with Academia	Increase in the number of people who continue consuming Lc-PLASMA in Japan and overseas. Lc-PLASMA contribute to the maintenance of immune function of our customers.	745 thousand people

21th Series of Unsecured Corporate Bond (Social Bonds) funding allocation and impact reporting (as of December 2025)

Project Name:	Capital investment, operation, and procurement of raw materials contributing to the production of Citicoline
Project Summary:	Citicoline is a substance that has long been used around the world to treat brain diseases. It is also used in health foods to support improved cognitive function. As the world's population continues to age, demand for this high-performance raw material is rapidly increasing. Kyowa Hakko Bio offers citicoline around the world as a health food additive or active pharmaceutical ingredient in accordance with the regulations in each country. Through this expansion of production capability, Kyowa Hakko Bio will establish a stable global supply network of citicoline to pharmaceutical and health food manufacturers. Despite intensifying competition, the overall market continues to expand, and Kyowa Hakko Bio has maintained a high market share in the United States. By broadening its business scope, the company achieved record-breaking sales again in fiscal year 2025. Kirin will continue to focus on the growth of Citicoline to solve the health challenges of customers worldwide and create both social and economic value.
2 高齢をゼロに 3 すべての人に健康と福祉を 9 産業と技術革新の基盤をつくろう	

Amount Allocated (Cumulative): 9.5 billion yen (58.7% Refinanced)

□ Impact reporting

Categories	Projects	Output	Outcome	FY 2025 commitment result
Businesses that contribute to the achievement of a society of health and longevity, through brain function improvement and brain function decline prevention	Capital investment, operation, and procurement of raw materials contributing to the production of Citicoline	☐ Increase in Citicoline manufacturing capacity	Increase in the number of users of products containing Citicoline (pharmaceuticals, health foods, etc.) in Japan and overseas. The products containing Citicoline contribute to brain function improvement and brain function decline prevention of our customers.	2.99 million people



Joy brings us together



21th Series of Unsecured Corporate Bond (Social Bonds) funding allocation and impact reporting (as of December 2025)

Project Name: Stock acquisition of Blackmores Limited.

Please refer to reporting of Kirin Holdings Company, Limited 22nd, 23rd unsecured straight bonds (Social bonds).

Amount Allocated (Cumulative): 1.8 billion yen (100% Refinanced)

□ Impact reporting

Please refer to reporting of Kirin Holdings Company, Limited 22nd, 23rd unsecured straight bonds (Social bonds).